QUOTE AND NEWS
FiercePharma  Jul 27  Comment 
Novartis is looking to distinguish its new med Cosentyx from a bevy of next-gen psoriasis-fighters with additional nods, including one for ankylosing spondylitis. But it's not the only company with that idea.
newratings.com  Jul 27  Comment 
Novartis Foundation confirms new members of its Board of trustees, including new Chairman Dr. Joerg Reinhardt Novartis International AG / Novartis Foundation confirms new members of its Board of trustees, including new Chairman Dr. Joerg...
FierceBiotech  Jul 24  Comment 
Novartis won accelerated approval for a promising oncology drug, gearing up to launch a new treatment for an advanced form of the most common type of skin cancer.
newratings.com  Jul 24  Comment 
BASEL (dpa-AFX) - Novartis (NVS) said that the US Food and Drug Administration has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has...
FiercePharma  Jul 24  Comment 
Novartis' recently acquired melanoma duo, Tafinlar and Mekinist, has won a recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use as a combo treatment for BRAF V600 mutation-positive melanoma
newratings.com  Jul 24  Comment 
Novartis drug Revolade® recommended by CHMP for EU approval to treat patients with severe aplastic anemia, a serious blood disorder Novartis International AG / Novartis drug Revolade® recommended by CHMP for EU approval to treat patients with...
newratings.com  Jul 24  Comment 
Novartis combination therapy Tafinlar® and Mekinist® achieves important EU and US regulatory milestones Novartis International AG / Novartis combination therapy Tafinlar® and Mekinist® achieves important EU and US regulatory milestones ....
FiercePharma  Jul 23  Comment 
A 10% revenue expansion in Novartis' generics unit Sandoz was one of the positives in the Swiss drugmaker's second quarter earnings, but it will not keep the drugmaker from closing three Sandoz plants next year and cutting about 770 jobs to...
newratings.com  Jul 23  Comment 
FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer Novartis International AG / FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma...




 

Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki